Form 4: Cytosorbents CFO Kathleen Bloch Reports Acquisition of Restricted Stock Units and Stock Options

Kathleen Bloch, CFO of Cytosorbents, reports the acquisition of 65,000 restricted stock units and 87,000 stock options.

Summary

• Kathleen P. Bloch, Chief Financial Officer of Cytosorbents Corp, filed a Form 4 on April 4, 2024, reporting transactions from April 2, 2024.
• The report details the acquisition of 65,000 shares of common stock in the form of restricted stock units (RSUs) and 87,000 stock options.
• The RSUs vest in equal parts on the first and second anniversaries of the grant date.
• The stock options vest over three years: one-half on the first anniversary, one-fourth on the second, and one-fourth on the third anniversary of the grant date.
• Following the reported transactions, Bloch beneficially owns 532,941 shares of common stock, including RSUs that vest upon continued service or a change in control.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices, indicating confidence in the company's future. There are no red flags or negative indicators.

Positives

• The grant of RSUs and stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize continued service and commitment to the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of RSUs and stock options is a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules described are typical for these types of grants, encouraging long-term commitment.

Stakeholder Impact

• The grant of equity to the CFO can positively impact shareholders by aligning management's interests with the company's long-term performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates